Gainers & Losers Of May 2: MOH, RGLS, EYES, APHB, CMRX...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of May 2, 2017.

GAINERS

1. Molina Healthcare Inc. (MOH)

Gained 17.62% to close Tuesday's (May 2) trading at $59.75.

News: The Company has replaced its CEO and CFO leading to takeover speculation.

Molina Healthcare CEO Mario Molina and CFO John Molina have been removed from their posts. Joseph White, Chief Accounting Officer, has been named Interim President and CEO.

The Board will immediately commence the search process for a permanent CEO. White has also been named the CFO of the Company.

The Company also reported better-than-expected Q1 results.

2. Regulus Therapeutics Inc. (RGLS)

Gained 12.12% to close Tuesday's trading at $1.85.

News: No news

Anticipated event:

The Company will provide first quarter 2017 financial results on Thursday, May 4, 2017 after the market closes.

3. Second Sight Medical Products Inc. (EYES)

Gained 10.26% to close Tuesday's trading at $1.29.

News: No news

Anticipated event:

The Company will release its first quarter financial results on Wednesday, May 3, 2017, after the close of the U.S. financial markets.

LOSERS

1. Aeterna Zentaris Inc. (AEZS)

Lost 33.33% to close Tuesday's trading at $0.90, plunging for the second straight day.

News: No news

Recent news:

Yesterday (May 1), the Company announced that its phase III study of drug candidate Zoptrex in women with locally advanced, recurrent or metastatic endometrial cancer, dubbed ZoptEC, failed to meet key goals. The news had sent the stock down 59.70% to $1.35.

2. Apollo Endosurgery Inc. (APEN)

Lost 19.95% to close Tuesday's trading at $6.50, plunging for the second straight day.

News: No news

The Company deals with less invasive medical devices for bariatric and gastrointestinal procedures.

Recent news: On March 8, 2017, the Company reported financial results for the fourth quarter and year ended December 31, 2016.

Net loss for the fourth quarter 2016 was $19.7 million or $35.01 per share on revenue of $15.4 million. This compared with a net loss of $5.4 million or $23.98 per share and revenue of $16.5 million in the fourth quarter 2015.

3. Sunesis Pharmaceuticals Inc. (SNSS)

Lost 18.99% to close Tuesday's trading at $2.96.

News: The Company has decided to withdraw its European Marketing Authorization Application for Vosaroxin as a treatment for relapsed/refractory acute myeloid leukemia.

During its recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP), the Company learnt that the committee was likely to formally adopt a negative opinion in its evaluation of the application.

4. AmpliPhi Biosciences Corp. (APHB)

Lost 18.18% to close Tuesday's trading at $1.98.

News: No news

Recent news: On May 1, the Company announced a new strategic emphasis on personalized therapies for serious or life-threatening antibiotic-resistant infections.

AmpliPhi expects to provide personalized phage therapies to patients suffering from severe, multidrug-resistant (MDR) infections who have failed prior therapies.

The Company has been informed by the FDA that "the clinical safety and effectiveness data collected during development, including from emergency case studies, could inform future discussions for clinical development and, ultimately, the regulatory pathway to approval."

AmpliPhi had cash of $2.2 million as of March 31, 2017, and expects the receipt of a $1.8 million tax incentive payment early in the third quarter of 2017.

5. Chimerix Inc. (CMRX)

Lost 11.01% to close Tuesday's trading at $5.21.

News: No news

Anticipated event:

The Company is slated to report financial results for the first quarter ended March 31, 2017, on Tuesday, May 9, 2017, before the market opens.